Skip to content

Plasma NGAL in APN Patients

Plasma NGAL as a Predictor to Acute Pyelonephritis : Case -Control Cohort Study .

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06802796
Enrollment
120
Registered
2025-01-31
Start date
2024-02-01
Completion date
2024-06-01
Last updated
2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pyelonephritis

Brief summary

In recent years, novel biomarkers of renal dysfunction have attracted attention for the diagnosis of UTIs. NGAL is a 25 kDa protein that belongs to the lipocalin. It acts as a transporter for small hydrophobic molecules and is involved in many physiological processes, such as modulating inflammation, innate immune response, and maintaining metabolic homeostasis

Interventions

DIAGNOSTIC_TESTPlasma NGAL test

Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL. Procedure was done according to the manufacturer's instructions.

Sponsors

Kafrelsheikh University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* above 20 years Suspected have pyelonphirtis

Exclusion criteria

* age below 20

Design outcomes

Primary

MeasureTime frameDescription
Result of plasma NGAL testOne dayResult of serum test of NGAL

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026